Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Short-Term Debt: ¥572 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600222 Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
62 GF Score
Price ¥7.91
GF Value ¥4.96
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Henan Taloph Pharmaceutical Stock Co Short-Term Debt?

Henan Taloph Pharmaceutical Stock Co SHSE:600222 -3.18% 62 Short-Term Debt is ¥572 Mil as of Jun. 2026. GuruFocus rates SHSE:600222 with a GF Score™ of 62/100 and a GF Value™ of ¥4.96 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Henan Taloph Pharmaceutical Stock Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥572 Mil.

Henan Taloph Pharmaceutical Stock Co's quarterly Short-Term Debt increased from Dec. 2025 (¥507 Mil) to Mar. 2026 (¥610 Mil) but then declined from Mar. 2026 (¥610 Mil) to Jun. 2026 (¥572 Mil).

Henan Taloph Pharmaceutical Stock Co's annual Short-Term Debt increased from Dec. 2023 (¥382 Mil) to Dec. 2024 (¥663 Mil) but then declined from Dec. 2024 (¥663 Mil) to Dec. 2025 (¥507 Mil).

Henan Taloph Pharmaceutical Stock Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Henan Taloph Pharmaceutical Stock Co Short-Term Debt Related Terms

Henan Taloph Pharmaceutical Stock Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Henan Taloph Pharmaceutical Stock Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Henan Taloph Pharmaceutical Stock Co Short-Term Debt Chart

Henan Taloph Pharmaceutical Stock Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 973.58 404.87 381.84 663.42 507.49

Henan Taloph Pharmaceutical Stock Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 712.49 638.59 507.49 609.81 571.59
SHSE:600222
62GF Score
Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥572 Mil mean?
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) has a Short-Term Debt of ¥572 Mil as of Jun. 2026.
Is Henan Taloph Pharmaceutical Stock Co's Short-Term Debt too high?
Henan Taloph Pharmaceutical Stock Co's current Short-Term Debt is ¥572 Mil. Overall, Henan Taloph Pharmaceutical Stock Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Henan Taloph Pharmaceutical Stock Co's Short-Term Debt compare to ZTS?
Henan Taloph Pharmaceutical Stock Co's Short-Term Debt of ¥572 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Henan Taloph Pharmaceutical Stock Co's current Short-Term Debt is ¥572 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Taloph Pharmaceutical Stock Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co (SHSE:600222) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.96, compared to a current price of ¥7.91 — trading 59.5% above its estimated fair value. The current Short-Term Debt is ¥572 Mil. Henan Taloph Pharmaceutical Stock Co's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Henan Taloph Pharmaceutical Stock Co (SHSE:600222), the current Short-Term Debt is ¥572 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Overvalued in 2026?

Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co stock appears to be overvalued. The current stock price of ¥7.91 is trading 59.5% above its estimated GF Value™ of ¥4.96. GuruFocus considers Henan Taloph Pharmaceutical Stock Co to be Significantly Overvalued.

Key valuation signals for SHSE:600222:

  • Short-Term Debt: ¥572 Mil
  • GF Value™: ¥4.96 vs. price of ¥7.91 (59.5% above fair value)
  • GF Score™: 62/100 with 9 warning signs

No single metric tells the full story. See the SHSE:600222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Henan Taloph Pharmaceutical Stock Co Business Description

Address No. 8, Jinsuo Road, High-tech Industrial Development Zone, Henan Province, Zhengzhou, CHN, 450001
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in pharmaceutical manufacturing and pharmaceutical research and development services, including pharmaceutical preparations, Chinese herbal medicine slices, and pharmaceutical research and development services. The company's pharmaceutical preparation business is mainly based on oral Chinese medicine preparations, and its treatment areas cover the respiratory system, cardiovascular and cerebrovascular system, digestive system, and nervous system.
62GF Score

Get the complete analysis for SHSE:600222

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.91
Price
¥4.96
GF Value